Study shows higher dose of DHA is linked to lower rate of early preterm birth

Children

Women taking 1,000 mg of docosohexanoic acid (DHA) daily in the last half of pregnancy had a lower rate of early preterm birth than women who took the standard 200 mg dose, according to a study funded by the National Institutes of Health. Women who entered the study with the lowest DHA level had the greatest reduction in early preterm birth, which is birth before 34 weeks of pregnancy and which increases the risk of infant death and disability

The study was conducted by Susan E. Carlson, Ph.D., at the University of Kansas Medical Center, Kansas City, and colleagues. It appears in EClinicalMedicine. Funding was provided by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Previous studies on DHA and other omega-3 fatty acids, which are nutrients found in fish and eggs and supplements like algal oil, and their possible effects on the rate of early preterm birth have been inconclusive and have not identified a specific type or dose of omega-3 fatty acids.

Researchers enrolled nearly 1,100 women and compared the early preterm birth rate of women given 1,000 mg of DHA to those given 200 mg. Overall, 1.7% of women in the high dose group delivered early preterm compared to 2.4% in the standard dose group.

Women in the high dose group with low DHA levels at study entry had the greatest reduction in early preterm birth (2% rate, compared to a 4.1% rate for those with low DHA levels on the standard dose).Among women who had high DHA levels at study entry, the rate of early preterm birth was low and did not differ by dose (1.4% vs. 1.1%). The authors called for screening DHA levels in pregnancy so that women with low levels could consider taking a higher daily dose.

Products You May Like

Articles You May Like

Looking For Essential, Affordable Bike Shorts? These Picks From Target Start at $7
Does Grandma Need Surgery for That Broken Wrist?
U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
‘We Call This Scope-a-Dope’: What We Heard This Week
Increased levels of moderate and vigorous physical activity can curb arterial stiffening in children

Leave a Reply

Your email address will not be published. Required fields are marked *